Canada's Eupraxia Pharmaceuticals Q3 net loss widens on higher R&D costs
EPRX•Eupraxia Pharmaceuticals reported a third-quarter net loss of $15.2 million, citing higher research and development and administrative costs. It reached target enrollment for its Phase 2b RESOLVE trial and expects its cash runway to extend into the second half of 2028.
1. Quarterly results and outlook
Eupraxia Pharmaceuticals said its third-quarter net loss widened as research and development and administrative costs increased while it expanded the Phase 2b RESOLVE trial. The company reached target enrollment in the trial and expects an interim analysis in December 2026. It also expects to release more data from its Phase 1b/2a RESOLVE trial in the coming months; 52-week data showed 64% of patients in clinical remission and meaningful histologic improvements.
